Patents by Inventor Michael DIDONATO

Michael DIDONATO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11136366
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Patent number: 11122825
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: September 21, 2021
    Assignee: Novartis AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • Publication number: 20210155713
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: May 29, 2019
    Publication date: May 27, 2021
    Inventors: Michael DIDONATO, Christoph ERKEL, Anna Galkin, Scott GLASER, Klaus Felix HARTLEPP, Yong JIA, Alexandra KRAUS, Christian Cho-Hua LEE, Sarah Michelle RUE, Jian SHI, Xenia Karola WEZLER
  • Publication number: 20200362058
    Abstract: The present invention provides antibody cytokine engrafted (ACE) proteins, including those that stimulate intracellular signaling, and are useful in the treatment of cancer, immunotherapy and metabolic disorders. In particular, the provided ACE protein compositions provide preferred biological effects over wild type cytokine proteins. For example, the provided ACE proteins can convey improved half-life, stability and produceability over the corresponding recombinant cytokine formulations.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 19, 2020
    Inventors: Michael DiDonato, Glen Spraggon
  • Publication number: 20200270334
    Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
    Type: Application
    Filed: May 22, 2018
    Publication date: August 27, 2020
    Inventors: Jonathan Deane, Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Glen Spraggon
  • Publication number: 20200113974
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Application
    Filed: May 22, 2018
    Publication date: April 16, 2020
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shellly Meeusen, Glen Spraggon
  • Publication number: 20190241636
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: October 18, 2018
    Publication date: August 8, 2019
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Patent number: 10144768
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 4, 2018
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Publication number: 20170158747
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: December 1, 2016
    Publication date: June 8, 2017
    Inventors: Michael DIDONATO, Mark KNUTH, Shelly MEEUSEN, Glen SPRAGGON